It is also noteworthy that while high JAM-A and HER2 co-expression was only on the boundary of a statistically significant correlation with poor recurrence-free survival or overall survival in HER2-positive breast cancer patients, addition of FOXA1 into the analysis was sufficient to tip this into statistical significance. The gene discussed is FOXA1; the disease is breast carcinoma.